News

Cosentyx is a fully human interleukin-17A (IL-17A) inhibitor, which showed speedy and sustained long term efficacy in treating patients with moderate-to-severe psoriasis, psoriatic arthritis (PsA) and ankylosing spondilytis

As announced in a press release dated November 7, 2017, a previous U.S Phase III study did not meet its primary endpoint – change in worst leg pain

QVAR® RediHaler™ is the first and only breath-actuated aerosol inhaled corticosteroid for the maintenance treatment of asthma as a prophylactic therapy in patients 4 years of age and

The approval is for the expanded use of Imfinzi to treat NSCLC patients whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy (CRT). Imfinzi, which

The funding has been allotted to spend over five years across eight CTUs in Cardiff, Birmingham, Glasgow, Southampton, Leeds and London. The CTUs are engaged in the designing, delivery

NF1 is an incurable genetic condition that affects one in 3,000 births, with highly-variable symptoms, including cutaneous (skin), neurological (nervous system) and orthopaedic (skeletal) manifestations. NF1 can cause

Fluarix Tetra has been approved in Europe to include adults and now children from six months of age for the prevention of influenza disease caused by the two

Headquartered in New York, Flatiron Health is a provider of oncology-specific electronic health record (EHR) software. The company, which was founded in 2012, is also engaged into curation

The proceeds from the commitment will be used to refinance Veloxis's outstanding debt, accelerate the growth of Envarsus XR in the US and help fund working capital of